CTLA4 and neoplasm: In tumor bearing mice, crizotinib increased the expression of the PD-1 (and LAG-3 but neither CTLA-4 nor TIM-3) on circulating CD4+ or CD8+ T lymphocytes (Supplementary Figs. 15, 16).